Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA
Higher dose of Wegovy® provided average weight loss of 21% in people…
Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss…
More Than a Symposium: IOF Builds Momentum Toward the Future of Orthodontics
HONG KONG, June 03, 2025 (GLOBE NEWSWIRE) -- The International Orthodontics Foundation…